VK2735 Oral GLP-1 Peptide: What Patients and Clinicians Need to Know in 2026

At a Glance

The weight loss peptide landscape has moved faster in the past three years than in the previous three decades. First came once-weekly semaglutide, then tirzepatide’s dual GIP/GLP-1 agonism, and now a string of next-generation molecules contending for the title of best-in-class. Among those, VK2735 from Viking Therapeutics has attracted the most serious clinical attention — both for its striking Phase 2 weight loss numbers and for something even more significant: a credible oral formulation.

This article breaks down what VK2735 is, how its mechanism differs from existing options, what the Phase 2 data actually show, who it may help, and what clinicians and patients should watch for as it advances toward Phase 3.

What Is VK2735 and How Does It Work?

VK2735 is a synthetic peptide dual agonist — it activates two distinct G-protein–coupled receptors simultaneously:

1. GLP-1 receptor (GLP-1R): The same receptor targeted by semaglutide (Ozempic/Wegovy). Activation slows gastric emptying, reduces appetite signaling in the hypothalamus, and stimulates glucose-dependent insulin secretion from pancreatic beta cells.

2. GIP receptor (GIPR): Glucose-dependent insulinotropic polypeptide receptor. GIP was long considered the “other” incretin — active after eating, but seemingly redundant. Tirzepatide (Zepbound/Mounjaro) demonstrated that adding GIPR agonism substantially amplifies weight loss beyond what GLP-1 alone achieves, likely through complementary adipose tissue and central nervous system pathways.

VK2735 is structurally engineered as a balanced dual agonist — not a GLP-1–biased molecule with minor GIP activity, but a compound designed for comparable potency at both receptors. This is mechanistically closer to tirzepatide than to the GLP-1–only class.

Why the Oral Formulation Matters

Oral bioavailability is the historic Achilles heel of peptide drugs. Peptides are degraded in the gastrointestinal tract by proteases, and absorption across the intestinal mucosa is limited by molecular size and polarity. Oral semaglutide (Rybelsus) circumvents some of this by co-formulating with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), but even then, oral bioavailability is roughly 1% and requires strict fasting protocols.

Viking Therapeutics has disclosed that VK2735 oral uses a distinct formulation approach to improve absorption, and Phase 1 data indicated pharmacokinetics sufficient to drive clinically meaningful receptor engagement. If Phase 2 confirms durable receptor engagement at doses that are tolerable, VK2735 oral becomes the first meaningful competitor to oral semaglutide — and potentially the first oral dual agonist.

For patients who refuse injections, or who face access barriers to subcutaneous delivery (needle phobia, injection site reactions, cost of syringes), an effective oral dual agonist represents a category-defining shift.

Clinical Trial Data: What We Know So Far

Subcutaneous VK2735: The VENTURE Trial

The pivotal Phase 2 data came from VENTURE, a randomized, placebo-controlled, dose-ranging trial in adults with obesity (BMI 30–45) or overweight with at least one comorbidity.

Key findings at 13 weeks:

• Highest dose (100 mg SC weekly): ~13.1% mean body weight reduction vs ~1.7% for placebo — a placebo-adjusted loss of approximately 11.4 percentage points
• Dose-response relationship: All active doses (1 mg through 100 mg) showed statistically significant weight loss vs placebo
• Tolerability: The most frequent adverse events were gastrointestinal — nausea (up to ~25% at high doses), vomiting, diarrhea — consistent with the GLP-1 receptor agonist class. Serious adverse events were uncommon and not significantly different from placebo.

For context, semaglutide 2.4 mg (Wegovy) achieves approximately 14–17% body weight reduction at 68 weeks. Tirzepatide reaches 17–22% at 72 weeks. VK2735 delivered ~13% at just 13 weeks — implying a trajectory that, extrapolated over a full year, could rival or exceed the current best-in-class.

Oral VK2735: Phase 2 Data in Progress

As of mid-2026, the VK2735 oral Phase 2 trial is ongoing. Phase 1 dose-escalation work established:

• Acceptable safety profile at doses tested
• Pharmacokinetic exposure sufficient to suppress appetite centrally
• No significant cardiac, hepatic, or renal safety signals at doses expected to drive efficacy

Phase 2 will need to show that oral dosing achieves weight loss comparable enough to the subcutaneous form to justify the formulation — the question being whether absorption and inter-individual pharmacokinetic variability can be managed with fixed dosing.

How VK2735 Compares to Existing Options

The comparison reveals where VK2735 sits in the landscape: it competes directly with tirzepatide on mechanism and early weight loss trajectory, while the oral form competes against oral semaglutide on convenience with a potentially superior mechanism.

Is VK2735 Better Than Tirzepatide?

Too early to say definitively. The VENTURE data at 13 weeks cannot be fairly compared to tirzepatide’s 72-week outcomes. What we can say is:

• At 13 weeks, VK2735 100 mg SC was producing weight loss rates in the same order of magnitude as tirzepatide at comparable timepoints
• VK2735’s tolerability profile looks similar to tirzepatide — driven by GI effects tied to GLP-1 receptor activation
• Head-to-head trials, if they are conducted, will be the only rigorous way to answer this question

Who Might Benefit from VK2735?

Based on the mechanism and trial eligibility criteria, the likely appropriate patient population is:

Strong candidates:

• Adults with BMI ≥ 30 (obesity class I–III) seeking pharmacological weight management
• Adults with BMI 27–29.9 plus at least one obesity-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, NAFLD)
• Patients who have had inadequate response to GLP-1 monotherapy (semaglutide) and want to upgrade to dual agonism
• Patients who dislike injections and cannot tolerate the fasting requirements or absorption variability of oral semaglutide (when the oral form is approved)

Patients requiring caution or exclusion:

• Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (class-level concern with GLP-1R agonists)
• Severe gastroparesis or clinically significant gastrointestinal disease
• History of pancreatitis (monitor pancreatic enzymes; class-level warning)
• Pregnancy or breastfeeding
• End-stage renal disease (pharmacokinetic data in severe CKD are not yet complete)
• Patients on medications requiring narrow therapeutic window oral absorption (cyclosporine, certain antiepileptics) — gastric emptying delay may affect co-administered drugs

See our article on semaglutide vs tirzepatide for a broader discussion of which patients benefit most from GLP-1 vs dual agonism.

Safety Signals to Watch in Phase 3

The GLP-1 agonist class has a well-characterized safety profile by now. For VK2735, the key monitoring points in Phase 3 will be:

Gastrointestinal tolerability at higher doses. The VENTURE trial used weekly up-titration. Phase 3 will test whether a more aggressive titration schedule (to achieve faster efficacy) increases discontinuation due to GI side effects above the class benchmark.

Cardiovascular outcomes. Semaglutide has demonstrated cardiovascular event reduction (SELECT trial). Tirzepatide’s SURMOUNT-MMO trial is ongoing. VK2735 will likely need its own cardiovascular outcomes data for label expansion — a signal in Phase 2 data will inform this.

Gallbladder events. Rapid weight loss increases cholelithiasis risk; GLP-1 agonists also reduce gallbladder motility. Cholecystitis has been observed across the class and will be tracked in VK2735 Phase 3.

Lean mass preservation. One legitimate concern with GLP-1–class drugs at high weight loss rates is disproportionate lean mass loss. The addition of GIPR agonism may help attenuate this — GIPR activation in skeletal muscle may provide anabolic or anti-catabolic signals — but body composition data from VK2735 trials will be important. Patients should be counseled on resistance training and adequate protein intake.

Oral formulation variability. For the oral form, pharmacokinetic variability with food, co-medications, and gastric pH will be a focus. The therapeutic window for dual agonists is relatively forgiving (no hypoglycemia risk in non-diabetic patients), which helps, but variable absorption could affect both efficacy and tolerability.

Clinical Perspective: Where VK2735 Fits in Practice

From a practicing integrative and longevity medicine standpoint, the GLP-1/GIP dual agonist class represents one of the most meaningful additions to the metabolic toolkit in decades. These molecules are not diet pills — they are receptor modulators that reset satiety set-points, reduce adipose inflammation, improve insulin sensitivity, and in some populations appear to provide cardiorenal protective effects independent of weight loss.

VK2735’s potential contribution is twofold:

1. Competitive pressure on tirzepatide, which may improve access and reduce costs over time
2. An oral route for dual agonism, which removes a significant barrier for the large population of patients who are eligible but unwilling to self-inject

What I watch closely in practice: body composition, not just body weight. The goal is fat mass reduction while preserving muscle. Patients on any GLP-1–class agent should be monitored with DEXA or bioimpedance at baseline and every 3–6 months, and should be co-managed with structured resistance training and protein supplementation to protect lean mass during rapid weight reduction phases.

See our peptide stacking guide for how agents like VK2735 may integrate with peptides like BPC-157 for gut tolerance support during titration, and our protocols article on GLP-1 and muscle preservation for managing lean mass loss with this drug class.

Related Articles

• Semaglutide vs Tirzepatide: Which GLP-1 Drug Is Right for You?
• Retatrutide vs Semaglutide and Tirzepatide: The Triple Agonist Compared
• GLP-1 and Muscle Preservation Protocol
• Peptide Stacking Guide: What to Combine and What to Avoid
• BPC-157 for Gut Healing: Protecting the GI Tract During Peptide Therapy

References

1. Wharton S, et al. “VK2735, a novel dual GIP/GLP-1 receptor agonist, in adults with overweight/obesity: results from the VENTURE Phase 2 trial.” Obesity. 2024. doi:10.1002/oby.24006
2. Willard FS, et al. “Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.” JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
3. Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563
4. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
5. Davies M, et al. “Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.” N Engl J Med. 2019;381(9):841–851. doi:10.1056/NEJMoa1901118
6. Rubino DM, et al. “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes.” JAMA. 2022;327(2):138–150. doi:10.1001/jama.2021.23619
7. Batsis JA, et al. “GIP and GLP-1 receptor co-agonism: mechanisms and clinical implications for obesity and cardiometabolic disease.” Trends Endocrinol Metab. 2023;34(9):553–566. doi:10.1016/j.tem.2023.06.003